Thyroid Pharmacology · Module 4 of 4

Radioiodine, Targeted Therapy, and Special Contexts

Thyroid cancer pharmacology, amiodarone thyroid disease, and pregnancy

The first 3 months of amiodarone therapy produce an expected pharmacological pattern — elevated free T4, low T3, high rT3, and transiently elevated TSH — that is a drug effect, not thyroid disease; do not treat; true amiodarone-induced thyrotoxicosis requires free T4 elevation persisting beyond this window with suppressed TSH and clinical thyrotoxicosis features; it comes in two mechanistically distinct types treated differently: type 1 (iodine-driven autonomous synthesis in pre-existing thyroid disease) → high-dose methimazole ± perchlorate; type 2 (destructive thyroiditis) → glucocorticoids; mixed type → both.
Recombinant human TSH (thyrotropin alfa) allows radioactive iodine administration while maintaining euthyroidism — 0.9 mg IM on two consecutive days raises TSH above 100 mIU/L at 24 hours, equivalent to 4-week levothyroxine withdrawal for low-to-intermediate-risk remnant ablation; withdrawal remains necessary for high-risk patients with known metastases requiring dosimetry; low-iodine diet below 50 mcg/day is required regardless of stimulation method.
TSH suppression in differentiated thyroid cancer is risk-stratified and dynamically reassessed — high-risk (metastases) TSH <0.1 mIU/L; intermediate-risk 0.1–0.5 mIU/L; low-risk after excellent response 0.5–2.0 mIU/L; prolonged suppression below 0.1 mIU/L causes cortical bone mineral density loss (fracture risk in postmenopausal women) and 2–3× atrial fibrillation risk in patients over 60; de-escalate at earliest clinical opportunity.
Neonatal Graves' disease has a 3–7 day delayed onset — maternal antithyroid drug suppresses the fetal thyroid in utero; as the drug clears postpartum while maternal TRAb persist, thyrotoxicosis emerges; a normal newborn screen TSH does not exclude delayed-onset disease; neonates born to mothers with TRAb >3× upper reference limit at 28–32 weeks require thyroid function tests at 48–72 hours and again at 7–10 days; the course is self-limited as maternal TRAb clear over 3–6 months.
Radioiodine-refractory differentiated thyroid cancer is treated with kinase inhibitors selected by molecular profile — sorafenib and lenvatinib (multi-kinase inhibitors targeting VEGFR/PDGFR/RAF) for RAI-refractory differentiated thyroid cancer; vandetanib and cabozantinib (RET + VEGFR) or selective RET inhibitors selpercatinib and pralsetinib for medullary thyroid cancer; dabrafenib plus trametinib (BRAF + MEK inhibition) for BRAF V600E-mutant anaplastic thyroid cancer.

Abbreviations: RAI = radioactive iodine · TSH = thyroid-stimulating hormone · rhTSH = recombinant human TSH (thyrotropin alfa) · T4 = thyroxine · T3 = triiodothyronine · rT3 = reverse triiodothyronine · TRAb = TSH receptor antibodies · DTC = differentiated thyroid cancer · MTC = medullary thyroid cancer · ATC = anaplastic thyroid cancer · VEGFR = vascular endothelial growth factor receptor · RET = rearranged during transfection · PTU = propylthiouracil · NIS = sodium-iodide symporter · AIT = amiodarone-induced thyrotoxicosis

Radioactive Iodine and TSH Suppression in Thyroid Cancer

Pre-RAI TSH Stimulation

rhTSH vs. Hormone Withdrawal

rhTSH (thyrotropin alfa): 0.9 mg IM ×2 days; RAI on day 3; maintains euthyroidism — preferred low-to-intermediate-risk
Withdrawal: 4 weeks off levothyroxine (or 2 weeks off liothyronine); TSH >50 mIU/L but causes significant hypothyroid symptoms
Withdrawal required: high-risk patients with known metastases needing dosimetry
Low-iodine diet (<50 mcg/day, 1–2 weeks before) required regardless of method

TSH Targets — Risk-Stratified

Dynamic Reassessment Required

High-risk (metastases, gross extrathyroidal extension): TSH <0.1 mIU/L
Intermediate-risk: TSH 0.1–0.5 mIU/L
Low-risk after excellent response (>2 years): de-escalate to TSH 0.5–2.0 mIU/L
Thyroglobulin (stimulated by rhTSH) every 1–2 years; anti-Tg antibody trend if Tg assay interfered

Suppression Harms

Bone and Cardiovascular

Bone: cortical bone mineral density loss; fracture risk in postmenopausal women on sustained TSH <0.1 mIU/L; DEXA screen; consider antiresorptive therapy
Cardiovascular: atrial fibrillation risk 2–3× in patients >60; increased left ventricular mass; schedule AF monitoring annually
De-escalate to lowest tolerable TSH at earliest clinical opportunity

Amiodarone-Induced Thyrotoxicosis — Type 1 vs. Type 2

Feature	AIT Type 1 — Iodine-Driven	AIT Type 2 — Destructive
Mechanism	Iodine excess drives autonomous synthesis in pre-existing Graves' or nodular thyroid	Direct amiodarone cytotoxicity on follicular cells releases preformed hormone
Thyroid anatomy	Pre-existing goiter, nodular disease, or unrecognized Graves'	Normal or mildly enlarged gland — no pre-existing disease required
Color Doppler	Increased or normal vascularity	Absent or markedly reduced vascularity
Treatment	High-dose methimazole (40–60 mg/day) ± potassium perchlorate (to deplete intrathyroidal iodine)	Glucocorticoids (prednisone 40 mg/day, taper over 3 months) — thionamides NOT effective (no new synthesis)
Mixed type	Common and difficult to distinguish — combined methimazole + glucocorticoid when type uncertain; amiodarone often cannot be stopped (life-threatening arrhythmia)

Thyroid Disease in Pregnancy and Neonatal Graves'

Graves' Disease in Pregnancy

Free T4 Upper Third — Lowest Effective Dose

Target: free T4 in upper third of reference range (not TSH normalization)
Use lowest effective thionamide dose — both drugs cross placenta and can cause fetal hypothyroidism
PTU in 1st trimester → switch to methimazole at 16 weeks (Module 3 rules apply)
Block-and-replace contraindicated — excess fetal thionamide exposure at doses needed to block thyroid
Check thyroid function every 4 weeks and adjust to target
TRAb at 28–32 weeks: >3× upper reference limit → close neonatal monitoring mandatory
Gestational transient thyrotoxicosis (hCG-driven): self-limited; resolves by 14–20 weeks; no treatment needed

Neonatal Graves' — 3–7 Day Delayed Onset

Maternal Drug Clears; TRAb Persist

Maternal TRAb cross placenta and drive neonatal thyroid stimulation
Onset delayed 3–7 days: maternal antithyroid drug suppresses fetal thyroid in utero; as drug clears postpartum while TRAb persist, thyrotoxicosis emerges
Normal newborn TSH screen does NOT exclude delayed-onset disease
Surveillance: TFTs at 48–72 h and 7–10 days for neonates at risk; outpatient follow-up at 2 weeks mandatory
Treatment: methimazole 0.2–0.5 mg/kg/day + propranolol for tachycardia; no PTU (hepatotoxicity risk in neonates)
Self-limited: maternal TRAb clear over 3–6 months; progressive drug withdrawal

Chapter Complete — Thyroid Pharmacology (THYR) · Key Clinical Rules

The early amiodarone biochemical pattern is a drug effect, not disease. In the first 3 months: elevated free T4 + low T3 + high rT3 + transiently elevated TSH = expected pharmacological consequence of type 1 deiodinase inhibition and iodine load. Do not treat. True AIT requires free T4 elevation persisting beyond this window with suppressed TSH and clinical thyrotoxicosis. AIT type 1 (vascularity increased, pre-existing thyroid autonomy) needs methimazole ± perchlorate; AIT type 2 (vascularity absent, destructive thyroiditis) needs glucocorticoids. Mixed type: combine both. Amiodarone often cannot be stopped — treat thyrotoxicosis regardless.

Neonatal Graves' disease has a 3–7 day delayed onset and a normal newborn screen does not exclude it. The mechanism is drug clearance outpacing TRAb clearance. Neonates with maternal TRAb >3× upper reference limit need thyroid function tests at 48–72 hours and 7–10 days regardless of the initial screen result.

TSH suppression in thyroid cancer is risk-stratified and not permanent. De-escalation from TSH <0.1 mIU/L is appropriate at 2 years in low-risk patients with excellent biochemical response. Sustained suppression below 0.1 mIU/L causes cortical bone loss and atrial fibrillation — both largely preventable by monitoring and early de-escalation.

Radioiodine-refractory thyroid cancer is now a molecularly matched disease. BRAF V600E drives de-differentiation in most RAI-refractory differentiated thyroid cancer; RET mutations drive medullary thyroid cancer; BRAF V600E drives anaplastic thyroid cancer. Selective inhibitors (selpercatinib, pralsetinib for RET; dabrafenib + trametinib for BRAF V600E ATC) have substantially better tolerability than first-generation multi-kinase inhibitors.

The 6-week steady-state rule and formulation-specific absorption considerations apply throughout thyroid hormone therapy. TSH in primary hypothyroidism; free T4 in central hypothyroidism; risk-stratified TSH targets in thyroid cancer; clinical endpoints in mifepristone-treated Cushing syndrome — thyroid hormone monitoring is always endpoint-specific.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Haugen BR et al.	2015 ATA management guidelines for thyroid nodules and differentiated thyroid cancer	Thyroid. 2016;26(1):1–133
Schlumberger M et al.	Strategies of radioiodine ablation in patients with low-risk thyroid cancer (HiLo trial)	N Engl J Med. 2012;366(18):1663–1673
Brose MS et al.	Sorafenib in radioactive iodine-refractory differentiated thyroid cancer (DECISION trial)	Lancet. 2014;384(9940):319–328
Schlumberger M et al.	Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT trial)	N Engl J Med. 2015;372(7):621–630
Wirth LJ et al.	Efficacy of selpercatinib in RET-altered thyroid cancers	N Engl J Med. 2020;383(9):825–835
Bogazzi F et al.	Approach to the patient with amiodarone-induced thyrotoxicosis	J Clin Endocrinol Metab. 2010;95(6):2529–2535
Alexander EK et al.	2017 ATA guidelines for thyroid disease during pregnancy and postpartum	Thyroid. 2017;27(3):315–389
van der Kaay DC et al.	Management of neonates born to mothers with Graves’ disease	Pediatrics. 2016;137(4):e20151878